Home » Cancer Dx Firm Pillar Biosciences Gets $18M Investment From ORI Healthcare

Cancer Dx Firm Pillar Biosciences Gets $18M Investment From ORI Healthcare

May 11, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Hong Kong-based venture capital group ORI Healthcare Fund announced today that it has made an $18 million investment in Boston-based cancer molecular diagnostics startup Pillar Biosciences.

According to ORI, Pillar is advancing a patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which offer high sensitivity and specificity, as well as a fast and affordable method for targeted NGS oncology testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Embryos Edited in US

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

True Blue

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

All the Plants

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

This Week in Nature

In Nature this week: a Danish reference genome, and more.

What's Popular?

In Molecular Diagnostics

  1. Thermo Fisher Scientific Q2 Revenues Up 10 Percent; Firm Increases 2017 Guidance Again

  2. Nanopore Sequencing, PCR Platforms Evaluated for Rapid Pneumonia Diagnosis in UK Study

    Premium

  3. Roche Diagnostics Revenues Up 5 Percent in First Half

  4. Qiagen, HTG Molecular Begin Second CDx Development Project

  5. As Need for Liquid Biopsy Reference Materials Grows, Commercial Vendors See Opportunity

    Premium

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.